These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29752026)
41. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626 [TBL] [Abstract][Full Text] [Related]
42. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants. Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513 [TBL] [Abstract][Full Text] [Related]
43. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Joensuu J; Koskenniemi E; Pang XL; Vesikari T Lancet; 1997 Oct; 350(9086):1205-9. PubMed ID: 9652561 [TBL] [Abstract][Full Text] [Related]
44. The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease. Glass RI; Tate JE; Jiang B; Parashar U J Infect Dis; 2021 Sep; 224(12 Suppl 2):S331-S342. PubMed ID: 34590142 [TBL] [Abstract][Full Text] [Related]
50. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486 [TBL] [Abstract][Full Text] [Related]
51. Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Xia S; Du J; Su J; Liu Y; Huang L; Yu Q; Xie Z; Gao J; Xu B; Gao X; Guo T; Liu Y; Zhou X; Yang H Vaccine; 2020 Oct; 38(46):7393-7400. PubMed ID: 32451212 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807 [TBL] [Abstract][Full Text] [Related]
54. Background rates of disease in Latin American children from a rotavirus vaccine study. Baay M; Bollaerts K; Struchiner C; Verstraeten T Hum Vaccin Immunother; 2017 Aug; 13(8):1916-1920. PubMed ID: 28441094 [TBL] [Abstract][Full Text] [Related]
55. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141 [TBL] [Abstract][Full Text] [Related]
56. The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan. Jones MA; Graves T; Middleton B; Totterdell J; Snelling TL; Marsh JA Trials; 2020 Aug; 21(1):741. PubMed ID: 32843086 [TBL] [Abstract][Full Text] [Related]
57. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants. Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027 [TBL] [Abstract][Full Text] [Related]
58. Live attenuated human rotavirus vaccine, Rotarix. Bernstein DI Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369 [TBL] [Abstract][Full Text] [Related]
59. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466 [TBL] [Abstract][Full Text] [Related]
60. The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity. Buyse H; Vinals C; Karkada N; Han HH Hum Vaccin Immunother; 2014; 10(1):19-24. PubMed ID: 24047799 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]